Ambros Therapeutics
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
18575 Jamboree Rd Ste 275-S, Irvine, Cal...Phone Number
(949) 508-0173Website
www.ambrostherapeutics.comRevenue
$8 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Ambros Therapeutics
Ambros Therapeutics, headquartered in Irvine, California, is a clinical-stage biotechnology company focused on the development of innovative and transformative medicines for diseases with a high unmet medical need.
Our lead investigational program targets complex regional pain syndrome type 1 (CRPS-1), a devastating rare disease that causes severe, unrelenting and frequently lasting pain following trauma to the bone or an injury. Patients may experience significant functional loss, sleep disturbance, and meaningful diminished quality of life and independence.Explore more
Ambros Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ambros Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Ambros Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Ambros Therapeutics
Check if Ambros Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Ambros Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Click to see if Ambros Therapeutics had a recent Job posting/layoffs
Ambros Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Ambros Therapeutics is spiking on competitors!
Product Launch: Get notified when Ambros Therapeutics launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Ambros Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Ambros Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Ambros Therapeutics.
Ambros Therapeutics Tech Stack
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Ambros Therapeutics News & Media
Little-Known HOWL Stock Skyrockets 100% on Biotech Merger News
Werewolf Therapeutics stock explodes higher on a merger agreement with Ambros Therapeutics. But is there any further upside left in HOWL shares?Werewolf Therapeutics Proposes Ambros Merger, $150M Placement | HOWL Stock News
Neridronate has been administered to about 600,000 patients in Italy; CRPS-RISE topline data are expected in 2028, with cash runway into 1H 2029.Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement
WALTHAM, Mass. and SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) and Ambros Therapeutics, Inc., today announced that they entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Ambros Therapeutics’ neridronate development program in Complex Regional Pain Syndrome Type 1 (“CRPS-1”, formerly known as Reflex Sympathetic Dystrophy). Upon completion of the merger, the combiWerewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement
WALTHAM, Mass. and SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) and Ambros Therapeutics, Inc., today announced that they entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Ambros Therapeutics’ neridronate development program in Complex Regional Pain Syndrome Type 1 (“CRPS-1”, formerly known as Reflex Sympathetic Dystrophy). Upon completion of the merger, the combi
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Ambros Therapeutics
Sign Up For FreeTo access detailed company insights
Ambros Therapeutics, headquartered in Irvine, California, is a clinical-stage biotechnology company focused on the development of innovative and transformative medicines for diseases with a high unmet medical need. Our lead investigational program targets complex regional pain syndrome type 1 (CRPS-1), a devastating rare disease that causes severe,... Read More
